Can weight loss injections cause mood swings?

Is there a direct link between GLP-1 medicines and mood changes?

The short answer is: not clearly established, but not dismissed either. The patient information leaflets for both tirzepatide (Mounjaro) and semaglutide (Wegovy) do not list depression or mood swings as common side effects. The large clinical trials (including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide) did not find a meaningful increase in psychiatric events compared with placebo groups.

That said, regulators including the MHRA and the European Medicines Agency have reviewed post-marketing reports of low mood, emotional blunting and, in isolated cases, suicidal ideation in people using GLP-1 medicines. Reviews completed in 2024 found insufficient evidence of a causal link, but surveillance continues. The Yellow Card scheme remains active for exactly this reason, real-world data collected after a medicine is licensed can reveal patterns that trial populations miss.

The honest position is that a small number of people do report feeling emotionally different on these medicines, and clinicians take those reports seriously even when the mechanism is not proven. If you notice persistent low mood, emotional detachment or unusual irritability after starting treatment, that is worth raising with your prescriber rather than waiting it out.

Could the physical side effects be driving the mood changes?

This is where the picture becomes clearer. GLP-1 receptor agonists commonly cause nausea, fatigue and changes in appetite, particularly in the first few weeks of a new dose. If you're eating significantly less, sleeping poorly because of nausea, or feeling physically drained, it would be surprising if that had no emotional consequence. Most people would feel irritable or low under those conditions regardless of the medicine.

The NHS patient information for tirzepatide describes nausea, headache, fatigue and dizziness as common effects, especially after starting or increasing a dose. These typically settle within days to a couple of weeks. Keeping the pen in the fridge door and taking it on the same day each week (a small routine that most patients land on naturally) helps you track whether symptoms follow the post-injection window or persist independently of it.

Rapid calorie restriction, even when it feels effortless because appetite has genuinely changed, can also affect serotonin and dopamine pathways. If your mood seems tied to how little you've eaten that day rather than to the injection itself, that pattern is worth sharing with your prescriber so they can assess whether your nutritional intake is adequate.

Who should be especially alert to this, and what should they do?

People with a personal or family history of depression, anxiety, bipolar disorder or other mental health conditions should mention this explicitly at the consultation stage, not because these medicines are contraindicated, but because a prescriber needs that context to monitor appropriately and to recognise early changes. The same applies to anyone currently taking antidepressants or mood-stabilising medication, since changes in weight and eating can themselves interact with how those medicines work.

There are other effects worth being aware of alongside mood. Hair thinning is another effect that sometimes surfaces during rapid weight loss, and understanding the fuller side-effect picture helps you distinguish what's expected from what needs attention. Similarly, if you have questions about longer-term safety signals that have attracted attention online, those pages address the evidence directly.

If at any point you experience thoughts of self-harm or suicide during treatment, stop and seek urgent medical help, call 999, go to A&E, or call 116 123 (Samaritans). Report the experience via the MHRA Yellow Card scheme so it contributes to the ongoing safety picture. These reports genuinely matter.

How does this affect the decision to start treatment?

For most people, the mood question doesn't change the risk-benefit calculation, particularly given that untreated obesity carries its own well-documented mental health burden, including higher rates of depression. Significant, sustained weight loss tends to improve mood and self-esteem in the medium term for many patients, and some people also ask whether B12 injections can contribute to weight loss as part of a broader approach to their health. The clinical trials showed broadly positive quality-of-life scores alongside the weight outcomes.

The right framing is probably this: mood effects are a reason to be monitored, not a reason to avoid treatment if you're otherwise a suitable candidate. A structured clinical review, which is part of every consultation at our pharmacy, gives you the space to flag mental health history and to agree a monitoring plan. You can read more about what the overall weight loss injection landscape looks like across medicines and doses, or explore how individual treatments are structured if you're still deciding which route makes sense.

If cost is also part of your thinking at this stage, an honest breakdown of what private treatment involves is covered on our cost page. And if you've reached the point where you'd like a prescriber to review your full picture, including any mental health history, a free consultation is the natural next step, speak to our prescribers and they'll assess your situation properly.